Aging is coupled with a progressive decline in cognitive abilities in a significant percentage of individuals. Such age-related cognitive impairment (ACI) is characterized by declines in the overall gray matter and hippocampus volumes (Harada et al., 2013; Sanford, 2017), with some changes commencing at ~20 years of age (Terry & Katzman, 2001). Many factors increase ACI risk, including neuroinflammation, diabetes, depression, hypothyroidism, number of surgeries, and cannabis use (Canet et al., 2003; Kodali et al., 2021; Luboshitzky et al., 1996; Shrivastava et al., 2011; Simen et al., 2011). Aging is also associated with pathological cognitive declines, including mild cognitive impairment (MCI) and Alzheimer’s disease (AD). MCI is typified by a greater cognitive decline than ACI but not severe enough to hinder daily living activities (Sanford, 2017). While ACI does not typically progress to dementia, a significant percentage of individuals with MCI progress into dementia or AD within five years of MCI diagnosis (Gauthier et al., 2006; Petersen et al., 2001). MCI affects 3–19% of adults older than 65 years old and is likely caused by several factors, including cholinergic neuronal loss, cerebrovascular disease, and amyloid deposition (Gauthier et al., 2006; Mufson et al., 2000). Dementia is typified by more severe and widespread cognitive and mood deficits, substantially interfering with daily function (Gauthier et al., 2006). The overall incidence of dementia has declined due to modifiable environmental factors (Satizabal et al., 2016). However, the number of people with dementia has enlarged due to increased life expectancy resulting from advances in public health, improved management of behavioral and social risk factors, and progress against cardiovascular diseases (Olshansky, 2015; Shetty et al., 2018).

An accurate diagnosis of ACI versus MCI, MCI versus AD, or predicting the progression of MCI into AD is challenging. Currently, objective diagnosing age-related cognitive impairment (ACI), mild cognitive impairment (MCI), and early-stage Alzheimer’s disease (AD) is a difficult task, as most cognitive impairment is clinically established via questionnaires, history, and physical examinations. A recent study has suggested that monitoring a miRNA triad, miR-181a-5p, miR-146a-5p, and miR-148a-3p can identify ACI and its progression to MCI and AD (Islam et al., EMBO Mol Med. 13: e14997, 2021). This commentary deliberates findings from this article, such as elevated levels of the miRNA triad in the brain impairing neural plasticity and cognitive function, the efficiency of measuring the miRNA triad in the circulating blood diagnosing MCI and AD, and the promise for improving cognitive function in MCI and AD by inhibiting this miRNA triad. Additional studies required prior to employing this miRNA triad in clinical practice are also discussed.

**KEYWORDS**
age-related cognitive impairment, Alzheimer’s disease, biomarkers, dementia, mild cognitive impairment, miRNAs

---

**Can mild cognitive impairment and Alzheimer’s disease be diagnosed by monitoring a miRNA triad in the blood?**

Zhuang-Yao D. Wei | Ashok K. Shetty

**Institute for Regenerative Medicine, Department of Molecular and Cellular Medicine, Texas A&M University Health Science Center College of Medicine, College Station, Texas, USA**

**Correspondence**
Ashok K. Shetty, Department of Molecular and Cellular Medicine, Institute for Regenerative Medicine, Texas A&M University Health Science Center College of Medicine, 1114 TAMU, 206 Olsen Boulevard, College Station, TX 77843-1114, USA.
Email: akskrs@tamu.edu

**Funding information**
National Institutes of Health - National Institute of Neurological Disorders and Stroke, Grant/Award Number: R01NS106907

**Abstract**
Objectively diagnosing age-related cognitive impairment (ACI), mild cognitive impairment (MCI), and early-stage Alzheimer’s disease (AD) is a difficult task, as most cognitive impairment is clinically established via questionnaires, history, and physical examinations. A recent study has suggested that monitoring a miRNA triad, miR-181a-5p, miR-146a-5p, and miR-148a-3p can identify ACI and its progression to MCI and AD (Islam et al., EMBO Mol Med. 13: e14997, 2021). This commentary deliberates findings from this article, such as elevated levels of the miRNA triad in the brain impairing neural plasticity and cognitive function, the efficiency of measuring the miRNA triad in the circulating blood diagnosing MCI and AD, and the promise for improving cognitive function in MCI and AD by inhibiting this miRNA triad. Additional studies required prior to employing this miRNA triad in clinical practice are also discussed.

**Abbreviations:** ACI, age-related cognitive impairment; AD, Alzheimer’s disease; APPPS, amyloid precursor protein/presenilin; CNS, central nervous system; IL-1β, interleukin-1 beta; MCI, mild cognitive impairment; miRNA, microRNA; mRNA, messenger RNA; MMSE, mini-mental state examination; ncRNA, noncoding RNA; RISC, RNA-induced silencing complex; TNF-alpha, tumor necrosis factor-alpha.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
the diagnostic criteria are primarily clinical and done with a comprehensive history, mini-mental state examination (MMSE), and neurological investigations. However, MMSE scores cannot objectively diagnose cognitive impairment because the results depend on patients’ attention state, cooperation, educational, and occupational background. On the contrary, laboratory and radiological studies are mostly done to rule out the other causes of dementia (Knopman et al., 2003). Specific biomarkers that could be used consistently to diagnose ACI, MCI, or AD are yet to be discovered. This commentary discusses the recent findings by Islam and colleagues that the cognitive status of individuals could be gleaned from studying changes in a microRNA (miRNA) triad in the circulating blood (Islam et al., 2021).

miRNAs are ~22 nucleotides long, have a post-transcriptional/translational regulatory target, and have diverse sequences. miRNAs can have tissue-specific expression patterns, and hence, changes in the characteristic of miRNAs are often used as a marker for disease (Zeng, 2006). miRNA genes are transcribed by RNA polymerase II to create a primary miRNA, which is processed first in the nucleus to form a 70-nucleotide long hairpin precursor and then cleaved by dicer to form the mature 22 nucleotide miRNA (Du & Zamore, 2005; Bushati & Cohen, 2007). A dicer protein complex also forms the RNA-induced silencing complex (RISC), which incorporates the mature miRNA to block, cleave or degrade the target mRNA (Bushati & Cohen, 2007).

Aging can influence the miRNA expression, with at least 115 miRNAs showing an association with aging (Somel et al., 2010). In mice, 70 different miRNAs display upregulation during brain aging, with 27 of those targeting genes of mitochondrial complexes involved in oxidative phosphorylation (Li et al., 2011). Changes in miRNA expression have also been considered to track the development of MCI. For example, the miR-132 family can distinguish MCI from ACI with 84–94% sensitivity and 96–98% specificity (Sheinerman et al., 2013). Furthermore, in AD, four miRNAs, miR-31, miR-93, miR-143, and miR-146a, are downregulated in the serum (Dong et al., 2015). Therefore, decreased or increased levels of specific miRNAs could be used as a biomarker of MCI or AD.

In an elegant study, Islam and colleagues discovered changes in a miRNA triad in the circulating blood that can assist in tracking the development of cognitive impairment and identify CNS pathological states that can progress into a declined cognitive state (Islam et al., 2021). In a mouse model, the study found a link between age-related spatial reference memory impairment and 55 differentially expressed miRNAs in the circulating blood. Notably, three miRNAs, miR-181a-5p, miR-146a-5p, and miR-148a-3p, capable of impacting decisive processes in preserving cognitive function in healthy people (Marioni et al., 2018), were substantially elevated. Since the principal biological activities affected by the expected targets of miR-181a-5p, miR-146a-5p, and miR-148a-3p comprise neuronal plasticity, GTPase-mediated signal transduction, and the response to transforming growth factor-beta, among others, the results suggested that these three miRNAs likely control vital processes linked to cognition that are dysregulated in ACI. Further analysis revealed that this miRNA triad also undergoes significant upregulation in the mouse brain from 13.5 to 16 months, coinciding with the learning impairment seen at 16.5 months. Such results implied that the increased expression of the miRNA triad preceded age-related cognitive decline, and increased blood levels of the three microRNAs denote pathophysiology in the brain (Islam et al., 2021).

Cell culture analysis revealed that miR-181a-5p and miR-148-3p were highly expressed in neurons. Administration of miR-181a-5p and miR-148-3p mimics led to downregulation of genes linked to synaptic plasticity and learning and memory, consistent with the role of these miRNAs in neurodegenerative diseases (Chen et al., 2019; Stepien et al., 2015). In contrast, miR-146a-5p was highly enriched in microglia, and increased levels of miR-146a-5p in microglia cultures resulted in the downregulation of genes linked to ncRNA processing and protein folding, the upregulation of proinflammatory cytokines, interleukin-1 beta (IL-1b), IL-6, and tumor necrosis factor-alpha (TNF-alpha) and downregulation of the antiinflammatory cytokine IL-10, consistent with the role of miR-146a-5p in inflammatory processes (Maschmeyer et al., 2018). Next, the authors compared gene expression changes mediated by the miRNA triad overexpression with the gene expression observed in CK-P25 mice, a mouse model for AD-like neurodegeneration (Fischer et al., 2005) and human AD patients. The results suggested that the genes and proteins downregulated in AD patients strongly overlapped with the downregulated genes observed in response to miR-148a-3p and miR-181a-5p. Furthermore, the addition of mimic oligonucleotides representing the 3-miRNAs to mouse primary hippocampal cell cultures reduced the number of synapses and aberrant neuronal activity (Islam et al., 2021).

The above results collectively suggested that elevated levels of miR-181a-5p, miR-146a-5p, and miR-148a-3p are detrimental to neural plasticity and cognitive function. Islam and associates next explored whether the miRNA triad in the circulating blood could detect MCI and AD (Islam et al., 2021). Indeed, the miRNA triad was significantly elevated in MCI patients compared to healthy patients, implying that elevated levels of these miRNAs signify increased cognitive impairment. Moreover, the study revealed a higher expression of miRNA triad in MCI patients advancing to AD, highlighting that the miRNA triad is elevated in MCI but undergoes further upregulation in MCI patients at risk for developing AD. Thus, the detection of the miRNA triad in the circulating blood could serve as a specific molecular marker to infer the cognitive status of patients. Furthermore, injection of a combination of inhibitory oligonucleotides against the miRNA triad into the hippocampus of 16.5-month-old mice resulted in the downregulation of the three miRNAs and better hippocampus-dependent memory function. When the inhibitory oligonucleotides against the miRNA triad were injected into the hippocampus of 7-month-old amyloid precursor protein/presenilin (APP/PS1) transgenic mice, a model of AD, the three miRNAs were downregulated, and hippocampus-dependent learning and memory functions were improved. Thus, the miRNA triad could be used not only as a biomarker for detecting cognitive decline but also as a potential therapeutic target (Islam et al., 2021).

Currently, when a patient sees a doctor for age-related cognitive problems, there are hardly any objective tests that could be used to
precisely diagnose ACI, MCI, or AD. Typically, the physician takes a
history, performs routine examination, and conducts cognitive func-
tion tests that are available at their disposal to assess the possibility
of ACI, MCI, AD, or any other conditions causing cognitive impair-
ment. Laboratory and radiological studies are only being utilized to
determine causes such as vitamin B12 deficiency or hypothyroidism.
There are no specific tools to track the extent of cognitive decline or
differentiate ACI, MCI, and AD. Therefore, the finding by Islam and
colleagues that a triad of specific miRNAs is upregulated in MCI and
increases further in MCI patients progressing into AD has implica-
tions (Islam et al., 2021). The study also suggested that the miRNA
triad could be a therapeutic target. Inhibition of the miRNA triad
expression led to a better cognitive function in both aged and AD mice.
Thus, investigation of this triad of miRNAs in the blood can serve as
a specific biomarker to screen patients at risk of developing patho-
logical cognitive impairment and track patients who already have
MCI and are at risk of developing AD. Such screening also allows the
application of promising therapeutic interventions to at-risk patients
or to halt the progression of cognitive decline in patients diagnosed
with MCI or early-stage AD.

In summary, Islam and colleagues discovered a miRNA triad that
promises to serve as a biomarker for ACI, MCI, and AD and a poten-
tial target for improving cognitive function in MCI and AD patients
(Islam et al., 2021). A cartoon summarizing the utility of evaluating
the miRNA triad in the circulating blood as a biomarker of MCI and
AD, and the miRNA triad serving as one of the mechanisms under-
lying impaired neural plasticity and cognitive function in MCI and
severe cognitive dysfunction in AD is illustrated (Figure 1). Although
these findings are exciting, additional studies are needed before
routinely employing this miRNA triad in clinical practice. The spec-
ificity of the triad of miRNAs for diagnosing MCI and AD need to
be further validated with larger sample sizes. Furthermore, there is
a concern that the three miRNAs suggested as biomarkers of MCI/
AD are also implicated in several other pathological processes. For
example, miR-181a-5p has been associated with colorectal cancer
(Han et al., 2017), osteoarthritis (Xue et al., 2018), and obesity
(Lozano-Bartolomé et al., 2018). Significantly, all three miRNAs are
associated with gastric cancer (Chen et al., 2013; Li et al., 2014; Song
et al., 2018).

The above issues raise the possibility that an underlying un-
related medical issue elevating the miRNA triad could lead to a
false-positive MCI/AD diagnosis, causing a devastating effect on
the patient. Therefore, steps need to be implemented to evaluate
the extent of misdiagnosis frequency and probability before being
widely recommended in clinical practice. A standardized extent of
miRNA triad elevation needs to be established in MCI/AD patients
lacking other diseases vis-à-vis MCI/AD patients with gastric cancer
or patients with only gastric cancer. Moreover, the extent of miRNA
triad elevation in aged and AD animal models with or without gastric
cancer or other disease states might reveal statistically significant
differences in miRNA triad levels in MCI/AD versus MCI/AD plus
other diseases (Beneditti et al., 2021; Carella et al., 2021; Moreira-
Costa et al., 2021). Also, when patients present with other signif-
icanent medical issues along with symptoms of MCI/AD, the degree
of miRNA triad elevation would need to be assessed and compared
to a standard set of values to discern whether the range falls within
MCI/AD only, MCI/AD plus a concomitant medical condition, or only
a confounding medical condition. However, such interpretation as-
sumes that the degree of miRNA triad elevation is directly linked to
the number of disease conditions a patient has. Alternatively, the
measurement of the miRNA triad in autopsied brain samples from
patients who have passed away from disease conditions unrelated
to MCI/AD may provide the extent of the false-positive rate if a cer-
tain percentage of patients exhibit elevated miRNA triad levels in the
absence of any behavioral and pathological hallmarks of MCI/AD.
Calculations can also be done for false negative, true negative, and

**FIGURE 1** The cartoon shows the promise of measuring miRNA triad
(miRs, 181a-5p, 146a-5p, and 148a-3p) in the circulating blood as a biomarker
of mild cognitive impairment (MCI) and Alzheimer’s disease (AD), and the miRNA
triad serving as one of the mechanisms underlying impaired neural plasticity and
cognitive function in MCI and severe cognitive dysfunction in AD. Increased
risk of MCI progression into AD with higher levels of miRNA triad expression
and the promise of an inhibitory oligonucleotide against the miRNA triad in
improving cognitive function in MCI and AD are also indicated.
true-positive rates with a similar study design. After such statistical studies provide a standardized value of miRNA triad elevation in different conditions, clinicians can better interpret miRNA triad results and explain them to the patient.

Finally, regarding the use of miRNA triad as a potential target for improving cognitive function in MCI and AD patients, additional studies investigating the effects of administration of miRNA triad inhibitors on other organ systems are needed. For example, miR-181a-5p has been shown to inhibit cancer cell migration and prevent cancer metastasis. Therefore, global inhibition of this miRNA to treat MCI or AD may be detrimental, exposing the patient to oncogenic effects (Li et al., 2015). Transient brain-specific inhibition of the miRNA triad is likely an alternative to avoid adverse systemic effects, which needs the development of advanced noninvasive approaches to accomplish that. Nonetheless, the miRNA triad is an exciting new development that promises to serve as a biomarker for ACI, MCI, and AD, with relevant additional investigations.

AUTHOR CONTRIBUTIONS
Zhuang-Yao Daniel Wei (Z-YDW) prepared the first draft of the manuscript text and the figure. Ashok K. Shetty (AKS) provided feedback to the first draft, edited, and finalized the manuscript text and the figure.

ACKNOWLEDGMENTS
The authors are supported by an R01 grant from the National Institutes of Health - National Institute of Neurological Disorders and Stroke (NIH-NINDS R01NS106907 to A.K.S.) and grants from the Department of Defense (W81XWH-17-1-0447 and W81XWH-19-1-0548 to A.K.S.). Zhuang-Yao Daniel Wei is supported by the Texas A&M College of Medicine. The figure was created with BioRender.com.

CONFLICT OF INTEREST
The authors declare that there are no competing interests.

DATA AVAILABILITY STATEMENT
All data needed to evaluate the conclusions of this commentary are present in the paper.

ORCID
Ashok K. Shetty https://orcid.org/0000-0001-5049-6671

REFERENCES
Benedetti, R., Papulino, C., Sgueglia, G., Chianese, U., De Marchi, T., Iovino, F., Rothii, D., Mai, A., Nimèus, E., Dell’Aversana, C., & Altucci, L. (2021). Regulatory interplay between mir-181a-5p and estrogen receptor signaling cascade in breast cancer. Cancers, 13(3), 543. https://doi.org/10.3390/cancers13030543
Bushati, N., & Cohen, S. M. (2007). MicroRNA functions. Annual Review of Cell and Developmental Biology, 23(1), 175–205. https://doi.org/10.1146/annurev.cellbio.23.090506.123406
Canet, J., Raeder, J., Rasmussen, L. S., Enlund, M., Kuipers, H. M., Hanning, C. D., Jolles, J., Korttila, K., Siersma, V. D., Dodds, C., Abildstrom, H., Sneyd, J. R., Vila, P., Johnson, T., Munoz Corsini, L., Silverstein, J. H., Nielsen, I. K., & Moller, J. T. (2003). Cognitive dysfunction after minor surgery in the elderly. Acta Anaesthesiologica Scandinavica, 47(10), 1204–1210. https://doi.org/10.1046/j.1399-6576.2003.00238.x
Carella, A., Marinelli, T., Armando, M., Pummo, D., Giovanni, M., Pasquale, D., & Angelo, B. (2021). Chapter 8 a short review on circulating micro-RNAs in diabetic patients. https://doi.org/10.9734/bpi/hmms/v15/10868D
Chen, G., Shen, Z.-L., Wang, L., Lv, C.-Y., Huang, X.-E., & Zhou, R.-P. (2013). Hsa-miR-181a-5p expression and effects on cell proliferation in gastric cancer. Asian Pacific Journal of Cancer Prevention, 14(6), 3871–3875. https://doi.org/10.7314/APJCP.2013.14.6.3871
Chen, L., Dong, R., Lu, Y., Zhou, Y., Li, K., Zhang, Z., & Meng, P. (2019). MicroRNA-146a protects against cognitive decline induced by surgical trauma by suppressing hippocampal neuroinflammation in mice. Brain, Behavior, and Immunity, 78, 188–201. https://doi.org/10.1016/j.bbi.2019.01.020
Dong, H., Li, J., Huang, L., Chen, X., Li, D., Wang, T., & Zhang, C.-Y. (2015). Serum miRNA profiles serve as novel biomarkers for the diagnosis of Alzheimer's disease. Disease Markers, 2015, e625659. https://doi.org/10.1155/2015/625659
Du, T., & Zamore, P. D. (2005). microPrimer: The biogenesis and function of microRNA. Development, 132(21), 4645–4652. https://doi.org/10.1242/dev.02070
Fischer, A., Sananbenesi, F., Pang, P. T., Lu, B., & Tsai, L.-H. (2005). Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory. Neuron, 48(5), 825–838. https://doi.org/10.1016/j.neuron.2005.10.033
Gauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., Broich, K., Belleville, S., Brodaty, H., Bennett, D., Chertkow, H., Cummings, J. L., de Leon, M., Feldman, H., Ganguli, M., Hampel, H., Scheltens, P., Tierney, M. C., Whitehouse, P., & Winblad, B. (2006). Mild cognitive impairment. The Lancet, 367(9518), 1262–1270. https://doi.org/10.1016/S0140-6736(06)68542-5
Han, P., Li, J.-W., Zhang, B.-M., Lv, J.-C., Li, Y.-M., Gu, X.-Y., Yu, Z.-W., Jiang, Y.-H., Bai, X.-F., Li, L. I., Liu, Y.-L., & Cui, B.-B. (2017). The IncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via mir-181a-5p-mediated regulation of Wnt/β-catenin signaling. Molecular Cancer, 16(1), 9. https://doi.org/10.1186/s12943-017-0583-1
Harada, C. N., Natelson Love, M. C., & Triebel, K. L. (2013). Normal cognitive aging. Clinics in Geriatric Medicine, 29(4), 737–752. https://doi.org/10.1016/j.cger.2013.07.002
Islam, M. R., Kaurani, L., Berulava, T., Heilbronner, U., Budde, M., Centeno, T. P., Elerdashwili, V., Zafieriou, M.-P., Benito, E., Sertel, S. M., Goldberg, M., Senner, F., Kalman, J. L., Burkhardt, S., Oepen, A. S., Sakib, M. S., Kerimoglu, C., Wirths, O., Bickeboller, H., … Fischer, A. (2021). A microRNA signature that correlates with cognition and is a target against cognitive decline. EMBO Molecular Medicine, 13(11), e13659. https://doi.org/10.15252/emmm.202013659
Knopman, D. S., Boeve, B. F., & Petersen, R. C. (2003). Essentials of the proper diagnosis of mild cognitive impairment, dementia, and major subtypes of dementia. Mayo Clinic Proceedings, 78(10), 1290–1308. https://doi.org/10.4065/78.10.1290
Kodali, M., Attaluri, S., Madhu, L. N., Shuai, B., Upadhya, R., Gonzalez, J. J., Rao, X., & Shetty, A. K. (2021). Metformin treatment in late middle age improves cognitive function with alleviation of microglial activation and enhancement of autophagy in the hippocampus. Aging Cell, 20(2), e13277. https://doi.org/10.1111/ace.13277
Li, H., Xie, S., Liu, M., Chen, Z., Liu, X., Wang, L. I., Li, D., & Zhou, Y. (2014). The clinical significance of downregulation of mir-124-3p, mir-146a-5p, mir-155-3p and mir-335-5p in gastric cancer tumorigenesis. International Journal of Oncology, 45(1), 197–208. https://doi.org/10.3892/ijo.2014.2415
Li, N., Bates, D. J., An, J., Terry, D. A., & Wang, E. (2011). Up-regulation of key microRNAs, and inverse down-regulation of their predicted oxidative phosphorylation target genes, during aging in mouse brain. *Neurobiology of Aging*, 32(5), 944–955. https://doi.org/10.1016/j.neurobiolaging.2009.04.020

Li, Y., Kuscu, C., Banach, A., Zhang, Q., Pulkoski-Gross, A., Kim, D., Liu, J., Roth, E., Li, E., Shroyer, K. R., Denoya, P. I., Zhu, X., Chen, L., & Cao, J. (2015). MIIR-181a-5p inhibits cancer cell migration and angiogenesis via downregulation of matrix metalloproteinase-14. *Cancer Research*, 75(13), 2674–2685. https://doi.org/10.1158/0008-5472.CAN-14-2875

Lozano-Bartolomé, J., Lauradó, G., Portero-Otin, M., Altuna-Coy, A., Rojo-Martínez, G., Vendrell, J., Jorba, R., Rodríguez-Gallego, E., & Chacón, M. R. (2018). Altered expression of miR-181a-5p and miR-23a-3p is associated with obesity and TGF-α-induced insulin resistance. *The Journal of Clinical Endocrinology & Metabolism*, 103(4), 1447–1458. https://doi.org/10.1210/jc.2017-01909

Luboshitzky, R., Oberman, A. S., Kaufman, N., Reichman, N., & Flatoe, E. (1996). Prevalence of cognitive dysfunction and hypothyroidism in an elderly community population. *Israel Journal of Medical Sciences*, 32(1), 60–65.

Marioni, R., McRae, A. F., Bressler, J., Colicino, E., Hannon, E., Li, S., Prada, D., Smith, J. A., Trevisi, L., Tsai, P.-C., Vojinovic, D., Simino, J., Levy, D., Liu, C., Mendelson, M., Satizabal, C. L., Yang, Q., Jhun, M., Kardia, S. L. R., … Deary, I. J. (2018). Meta-analysis of epigenome-wide association studies of cognitive abilities. *Molecular Psychiatry*, 23(11), 2133–2144. https://doi.org/10.1038/s41380-017-0008-y

Maschmeyer, P., Petkau, G., Siracusa, F., Zimmermann, J., Zügel, F., Kühl, A. A., Lehmann, K., Schimmelpfennig, S., Weber, M., Haftmann, C., Riedel, R., Bardua, M., Heinz, G. A., Tran, C. L., Hoyer, B. F., Hiepe, F., Herzog, S., Wittmann, J., Rajewsky, N., … Mashreghi, M.-F. (2018). Selective targeting of pro-inflammatory Th1 cells by microRNA-148a-specific antagonirs in vivo. *Journal of Autoimmunity*, 89, 41–52. https://doi.org/10.1016/j.jaut.2017.11.005

Moreira-Costa, L., Barros, A. S., Lourenço, A. P., Leite-Moreira, A. F., Nogueira-Ferreira, R., Thongboonkerd, V., & Vitorino, R. (2021). Exosome-derived mediators as potential biomarkers for cardiovascular diseases: A network approach. *Proteomes*, 9(1), 8. https://doi.org/10.3390/proteomes9010008

Mufson, E. J., Ma, S. Y., Cochran, E. J., Bennett, D. A., Beckett, L. A., Jaffar, S., & Kordower, J. H. (2000). Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer’s disease. *Journal of Comparative Neurology*, 427(1), 19–30.

Olishansky, S. J. (2015). Has the rate of human aging already been modified? *Cold Spring Harb Perspect Biol*, 7(12), a025965. https://doi.org/10.1101/cshperspect.a025965

Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., Ritchie, K., Rossor, M., Thal, L., & Winblad, B. (2001). Current concepts in mild cognitive impairment. *Archives of Neurology*, 58(12), 1985–1992. https://doi.org/10.1001/archneur.58.12.1985

Sanford, A. M. (2017). Mild cognitive impairment. *Clinics in Geriatric Medicine*, 33(3), 325–337. https://doi.org/10.1016/j.cger.2017.02.005

Satizabal, C. L., Beiser, A. S., Chouraki, V., Chêne, G., Dufouil, C., & Seshadri, S. (2016). Incidence of dementia over three decades in the Framingham heart study. *New England Journal of Medicine*, 374(6), 523–532. https://doi.org/10.1056/NEJMoai1504327

Sheinerman, K. S., Tsvinsky, V. G., Abdullah, L., Crawford, F., & Umanovsky, S. R. (2013). Plasma microRNA biomarkers for detection of mild cognitive impairment: Biomarker Validation Study. *Aging (Albany NY)*, 5(12), 925–938. https://doi.org/10.18632/aging.100624

Shetty, A. K., Kodali, M., Upadhyra, R., & Madhu, L. N. (2018). Emerging anti-aging strategies—scientific basis and efficacy. *Aging and Disease*, 9(6), 1165–1184. https://doi.org/10.14336/AD.2018.1026

Shrivastava, A., Johnston, M., & Tsuang, M. (2011). Cannabis use and cognitive dysfunction. *Indian Journal of Psychiatry*, 53(3), 187–191. https://doi.org/10.4103/0019-5545.86796

Simen, A. A., Bordner, K. A., Martin, M. P., Moy, L. A., & Barry, L. C. (2011). Cognitive dysfunction with aging and the role of inflammation. *Therapeutic Advances in Chronic Disease*, 2(3), 175–195. https://doi.org/10.1177/2040622311399145

Somel, M., Guo, S., Fu, N., Yan, Z., Hu, H. Y., Xu, Y., Yuan, Y., Ning, Z., Hu, Y., Menzel, C., Hu, H., Lachmann, M., Zeng, R., Chen, W., & Khaitovich, P. (2010). MicroRNA, mRNA, and protein expression link development and aging in human and macaque brain. *Genome Research*, 20(9), 1207–1218. https://doi.org/10.1101/gr.106849.110

Song, B., Du, J., Song, D., Ren, J., Feng, Y., Song, B., & Feng, Y. (2018). Dysregulation of NCAPG, KN1L, miR-148a-3p, miR-193b-3p, and miR-1179 may contribute to the progression of gastric cancer. *Biological Research*, 51, https://doi.org/10.1186/s40659-018-0192-5

Stepniak, B., Kästner, A., Poggi, M., Mitjans, M., Begemann, M., Hartmann, A., Van der Auwera, S., Sananbenesi, F., Krueger-Burg, D., Matuszko, G., Brosi, C., Homuth, G., Völzke, H., Benseler, F., Bagni, C., Fischer, U., Dityatev, A., Grabe, H.-J., Rujescu, D., … Ehrenreich, H. (2015). Accumulated common variants in the broader fragile X gene family modulate autistc phenotypes. *EMBO Molecular Medicine*, 7(12), 1565–1579. https://doi.org/10.15252/emmm.201505696

Terry, R. D., & Katzman, R. (2001). Life span and synapses: will there be a primary senile dementia? *Neurobiology of Aging*, 22(3), 347–348. https://doi.org/10.1016/S0197-4580(00)00250-5

Xue, J., Min, Z., Xia, Z., Cheng, B., Lan, B., Zhang, F., Han, Y., Wang, K., & Sun, J. (2018). The hsa-mir-181a-5p reduces oxidation resistance by controlling SECISBP2 in osteoarthritis. *BMJ Musculoskeletal Disorders*, 19(1), 355. https://doi.org/10.1136/bmjmuscloskel-2018-012273-6

Zeng, Y. (2006). Principles of micro-RNA production and maturation. *Aging (Albany NY)*, 374, 5–12. https://doi.org/10.1056/NEJMoai1504327

How to cite this article: Wei, Z.-Y. D., & Shetty, A. K. (2022). Can mild cognitive impairment and Alzheimer’s disease be diagnosed by monitoring a miRNA triad in the blood? *Aging Cell*, 21, e13627. https://doi.org/10.1111/acel.13627